Breaking News Instant updates and real-time market news.

MNTA

Momenta

$11.77

0.17 (1.47%)

, TEVA

Teva

$45.04

-0.02 (-0.04%)

05:45
10/11/16
10/11
05:45
10/11/16
05:45

Momenta upgraded to Overweight from Equal Weight at Barclays

Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.

MNTA

Momenta

$11.77

0.17 (1.47%)

TEVA

Teva

$45.04

-0.02 (-0.04%)

  • 13

    Oct

  • 14

    Oct

  • 06

    Nov

  • 15

    Nov

MNTA Momenta
$11.77

0.17 (1.47%)

08/25/16
JPMS
08/25/16
NO CHANGE
JPMS
Overweight
Invalidation of Copaxone patents a 'clear positive' for Momenta, says JPMorgan
JPMorgan analyst Chris Schott said the USPTO invalidating two Copaxone 40mg patents is the first step towards a potential 2017 or 2018 generic launch and a "clear positive" for Momenta (MNTA), which he views as the most likely near-term generic threat to the 40mg dose of the drug. For patent holder Teva (TEVA), however, he does not see this as a meaningful setback, noting that his estimates already reflected expectations for competition in 2017. The firm has Overweight ratings on both Momenta and Teva shares.
08/31/16
LEER
08/31/16
NO CHANGE
Target $61
LEER
Outperform
Teva price target lowered to $61 from $66 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva (TEVA) to $61 from $66 on loss of Copaxone patent challenge as an upside catalyst. The analyst believes Teva's share price implies a generic entrant sometime in the second half of 2017 after losing an Inter Partes Review decision on two Copaxone 40mg anchor patents. In order to mitigate EPS downside in 2017-2018 and eliminate business uncertainty, Gerberry thinks the company should settle its Copaxone patent dispute with Novartis (NVS) and Momenta (MNTA), which he sees as "the most credible" generic threat. The analyst reiterates an Outperform rating on Teva's shares.
09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
09/07/16
MAXM
09/07/16
DOWNGRADE
MAXM
Sell
Momenta downgraded to Sell from Hold at Maxim
TEVA Teva
$45.04

-0.02 (-0.04%)

10/03/16
WELS
10/03/16
NO CHANGE
WELS
Outperform
Teva shares suffering from lack of catalysts, says Wells Fargo
Wells Fargo analyst David Maris attributes the continued slide in Teva (TEVA) shares largely to negative sector news such as the drug pricing debate, fears on generic pricing, and Mylan's (MYL) EpiPen issue, but also thinks the slide has been made worse by Teva's lack of near-term catalysts. Additionally, the ongoing Copaxone generic trial and Teva's recently filed suit against Rimsa's founders over allegedly being misled by the Mexican pharmaceutical company have added to the pressure, Maris noted. Maris acknowledges there may be "no notable catalysts" for the rest of the year for Teva, but he thinks it should be a "robust 2017" for the company and keeps an Outperform rating on the shares.
10/05/16
WELS
10/05/16
NO CHANGE
WELS
Outperform
Teva estimates lowered on generic trends at Wells Fargo
Wells Fargo analyst David Maris lowered his estimates for Teva (TEVA) for this year and next, citing expectations for lower generic sales this year and lower margins in the generic business. Maris lowered his price target range for Teva shares to $60-$61 from $70-73 based on his lower estimates as well as the uncertainty of the environment, but keeps an Outperform rating on shares citing valuation and his belief 2017 should be a better year with several pipeline events for Teva.
10/06/16
WELS
10/06/16
NO CHANGE
WELS
Wells calls Teva partnership with Celltrion 'good news'
Wells Fargo analyst David Maris views Teva Pharmaceutical's partnership to commercialize two of Celltrion's monoclonal antibody biosimilar candidates as "good news." Teva is now a "little more firmly in the biosimilar game," Maris tells investors in a research note. He likes that the initial cash outflow is small and the partner. Maris has an Outperform rating on Teva.
10/07/16
LEER
10/07/16
NO CHANGE
Target $57
LEER
Outperform
Teva price target lowered to $57 from $61 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva to $57 from $61 and trimmed his estimates to reflect near-term headwinds and a more conservative Copaxone outlook. The analyst continues to view a generic Copaxone launch in late the second half of 2017 as a risk. Nonetheless, Gerberry reiterates an Outperform rating on the stock as he views shares as attractively valued despite near-term EPS concerns and believes investor attention will eventually pivot to Teva's attractive late stage pipeline.

TODAY'S FREE FLY STORIES

AKS

AK Steel

$6.54

-0.11 (-1.65%)

16:57
06/26/17
06/26
16:57
06/26/17
16:57
Hot Stocks
Breaking Hot Stocks news story on AK Steel »

Integrated Core…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

VNO

Vornado

$94.75

0.57 (0.61%)

16:51
06/26/17
06/26
16:51
06/26/17
16:51
Hot Stocks
Vornado sets July 7 as record date for JBG SMITH Properties spinoff »

Vornado announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATY

Cathay General

$36.99

0.08 (0.22%)

16:42
06/26/17
06/26
16:42
06/26/17
16:42
Syndicate
Breaking Syndicate news story on Cathay General »

Cathay General files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMCF

Emclaire Financial

16:39
06/26/17
06/26
16:39
06/26/17
16:39
Hot Stocks
Emclaire Financial appoints Engles as CFO, Lucco as risk and strategy chief »

Emclaire Financial,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIER

TIER REIT

$17.60

-0.07 (-0.40%)

, ECA

Encana

$8.42

-0.04 (-0.47%)

16:36
06/26/17
06/26
16:36
06/26/17
16:36
Hot Stocks
TIER REIT acquires Texas office tower, sells remaining Louisville portfolio »

TIER REIT (TIER)…

TIER

TIER REIT

$17.60

-0.07 (-0.40%)

ECA

Encana

$8.42

-0.04 (-0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 11

    Jul

AL

Air Lease

$36.84

0.28 (0.77%)

, BA

Boeing

$199.98

-2.25 (-1.11%)

16:34
06/26/17
06/26
16:34
06/26/17
16:34
Hot Stocks
Air Lease announces delivery of Boeing 737-800 to Royal Air Maroc »

Air Lease (AL) announced…

AL

Air Lease

$36.84

0.28 (0.77%)

BA

Boeing

$199.98

-2.25 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

PANL

Pangaea Logistics

$2.69

-0.1 (-3.58%)

16:34
06/26/17
06/26
16:34
06/26/17
16:34
Hot Stocks
Breaking Hot Stocks news story on Pangaea Logistics »

VR Advisory Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XL

XL Group

$43.62

0.21 (0.48%)

16:33
06/26/17
06/26
16:33
06/26/17
16:33
Hot Stocks
XL-Cayman waives financing condition for tender offers »

XL Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$17.08

1.28 (8.10%)

16:32
06/26/17
06/26
16:32
06/26/17
16:32
Hot Stocks
Breaking Hot Stocks news story on Valeant »

Paulson & Co. reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

TOPS

TOP Ships

$0.68

-0.12 (-15.00%)

16:31
06/26/17
06/26
16:31
06/26/17
16:31
Hot Stocks
TOP Ships reports $4.2M in cash, cash equivalents post reverse stock split »

TOP Ships reports its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCTI

PCTEL

$6.95

-0.21 (-2.93%)

16:31
06/26/17
06/26
16:31
06/26/17
16:31
Hot Stocks
PCTEL raises quarterly dividend 10% to 5.5c per share »

This dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

16:30
06/26/17
06/26
16:30
06/26/17
16:30
Options
Preliminary option volume of 13.3M today »

Preliminary option volume…

FNJN

Finjan Holdings

$3.62

-0.18 (-4.74%)

16:29
06/26/17
06/26
16:29
06/26/17
16:29
Syndicate
Finjan Holdings announces common stock offering, no amount given »

Finjan Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

16:20
06/26/17
06/26
16:20
06/26/17
16:20
Options
Closing CBOE SPX and VIX Index summary for June 26th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$88.17

3.34 (3.94%)

, LRLCY

L'Oreal

$43.61

1.53 (3.64%)

16:18
06/26/17
06/26
16:18
06/26/17
16:18
General news
On The Fly: Top stock stories for Monday »

The major averages began…

NSRGY

Nestle

$88.17

3.34 (3.94%)

LRLCY

L'Oreal

$43.61

1.53 (3.64%)

STOR

Store Capital

$23.11

2.34 (11.27%)

BRK.A

Berkshire Hathaway

$251,480.00

-320 (-0.13%)

BRK.B

Berkshire Hathaway

$167.47

0.25 (0.15%)

CAR

Avis Budget

$27.67

3.43 (14.15%)

GOOG

Alphabet

$952.27

-13.32 (-1.38%)

GOOGL

Alphabet Class A

$972.09

-14 (-1.42%)

HTZ

Hertz

$10.83

1.29 (13.52%)

AAPL

Apple

$145.82

-0.46 (-0.31%)

SGEN

Seattle Genetics

$56.55

-5.19 (-8.41%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$25.77

-0.11 (-0.43%)

SSYS

Stratasys

$24.39

-3.22 (-11.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

$NSD

NASDAQ Market Internals

16:17
06/26/17
06/26
16:17
06/26/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
06/26/17
06/26
16:16
06/26/17
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEWM

New Media

$13.62

0.27 (2.02%)

16:16
06/26/17
06/26
16:16
06/26/17
16:16
Hot Stocks
New Media rebrands propel business services unit, renames it UpCurve »

New Media Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALG

Alamo Group

$91.52

1.1925 (1.32%)

16:15
06/26/17
06/26
16:15
06/26/17
16:15
Hot Stocks
Alamo Group completes acquisition of Old Dominion Brush Company »

Alamo Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$111.10

-0.9 (-0.80%)

16:13
06/26/17
06/26
16:13
06/26/17
16:13
Syndicate
bluebird bio announces offering of $350M of common stock »

bluebird bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$53.74

-0.59 (-1.09%)

16:12
06/26/17
06/26
16:12
06/26/17
16:12
Periodicals
PayPal's Venmo tests debit card, Recode says »

PayPal's Venmo has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

KMPH

KemPharm

$3.40

0.05 (1.49%)

16:11
06/26/17
06/26
16:11
06/26/17
16:11
Hot Stocks
KemPharm granted patent for KP746, a prodrug of oxymorphone »

KemPharm announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:11
06/26/17
06/26
16:11
06/26/17
16:11
Conference/Events
Federal Reserve Bank President of San Francisco speaks on global growth »

San Francisco Federal…

SPLP

Steel Partners

$18.50

0.1 (0.54%)

, HNH

Handy & Harman

$28.50

-0.2 (-0.70%)

16:11
06/26/17
06/26
16:11
06/26/17
16:11
Hot Stocks
Steel Partners, Handy & Harman sign definitive merger agreement »

Steel Partners Holdings…

SPLP

Steel Partners

$18.50

0.1 (0.54%)

HNH

Handy & Harman

$28.50

-0.2 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESPR

Esperion

$42.87

-1.47 (-3.32%)

16:10
06/26/17
06/26
16:10
06/26/17
16:10
Hot Stocks
Esperion says FDA confirms pathway for approval of bempedoic, ezetimib combo »

Esperion Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.